These subsets may be defined by baseline characteristics, e.g., patients with certain biomarkers, age groups etc., or by post-baseline events, e.g., patients who survived till a certain timepoint, or who responded based on a success criterion
R&D pipeline: where are we now and whats next Currently, GLP-1s have received regulatory approval from both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of: T2D
Knowing which type you have is the first step toward effective tirzepatide side effect management
Explore our telemedicine weight loss program here
Significant weight loss
Enhanced metabolic function: Retatrutides unique activation of glucagon receptors adds to its appeal by boosting energy expenditure and metabolic rate, contributing to overall metabolic health